Petah Tiqwa, Israel
Petah Tiqwa, Israel
SEARCH FILTERS
Time filter
Source Type

News Article | May 4, 2017
Site: www.prfire.com

4NG takes up the baton from 4energy! 4NG Limited, the Next Generation Industrial IoT “Internet of Things” company, has acquired SMARTset and SMARTstation IoT and other assets of 4energy Limited, together with investment from experienced industry participants including Foster Environmental Limited, Upnorth Group Limited and AIT Partnership Group Limited. This new partnership will enable 4NG to roll out SMARTset software and SMARTstation hardware to the UK and international markets. SMARTset provides operational managers the tools to connect to any equipment, sensor or element of their built environment, irrespective of its protocol or vendor. It can analyse, predict, discover insights and centrally control remote equipment as well as provide first-class alarms and alerts. According to 4NG Managing Director & founder Steve O’Hara “There is great potential for SMARTset & SMARTstation across technical estates: data centres, communication rooms, street furniture and the industrial built environment for SME’s. Our investors have strong relationships with customers in these sectors which will help drive the expansion of 4NG.” Speaking on behalf of the new investors, Steven Bailey comments “We are all excited to join Steve O’Hara and the team on this journey. The customer benefits of the SMARTset and SMARTstation products are clear and we look forward to working closely with 4NG to bring their solution to customers in the UK and overseas”. AIT provides technical services and solutions for data centre management including data centre build and design, power and environmental monitoring systems and DCIM software integration; and secure networks from wireless networks and firewalls to point-to-point microwave radio links. Founded over 15 years ago AIT is a trusted advisor to some of the world’s largest organisations, with a passion for delivering innovation and excellent service and support. Foster Environmental experience in heating, ventilation, air conditioning (HVAC) and refrigeration spans four decades. Our fully trained and dedicated team has amassed an extensive breadth of industry knowledge across every element of heating, ventilation and air conditioning for commercial and industrial environments. We have also developed particular specialism in providing close control mechanical plant and associated electrical services to live technical data centres. Our turnkey solution for data centres, from the cooling plant and controls through to the IT network infrastructure, includes electrical power and lighting, hot and cold aisle containment, BMS, DCIM, fire suppression, life safety and security systems. Building Service Engineers who specialise in all aspects of Critical Facility Engineering. Particularly for the Data Centre and Telecommunications Sector in the UK & Ireland. We specialise in Infrastructure services and can assist you nationwide with design, consulting, optimisation, compliance, service, project plans and new build facilities.


Automated ticketing and mobility surveys by capturing multi-modal travel behaviour How to make public transport even more comfortable for passengers? Can ticketing be simplified? How to capture the actual mobility behavior? Public transport needs to be as efficient and comfortable as possible in order to be attractive for passengers and cost-effective for public transport operators. AIT addresses these challenges with its technology Travel Mode Identification (TMI), which is an innovative software solution automatically identifying travel modes of people carrying a smartphone. The technology can easily be integrated in existing smartphone-apps and automatically classifies eight different travel modes, no user intervention is required. Possible applications are e.g. simple and reliable mobility surveys and novel solutions for automated ticketing. Mobility Surveys Mobility surveys use to be a tremendous effort regarding both, cost and time. So far reams of questionnaires either in writing or by telephone had to be answered and analyzed. Not with TMI: The technology allows collecting data simply via smartphone at lower cost, in less time and higher quality. For this specific application AIT has launched the service "AIT Smart Survey" that has already been applied in several surveys e.g. in Vienna. Automated Ticketing TMI can also be used for integrated mobile ticketing apps for public transport: The technology detects whenever a smartphone user travels on public transport; detailed route information and fees can be calculated accordingly. This offers a maximum level of comfort to the passenger, who does not need to buy any ticket or press any button - it just works automatically. The public transport operator benefits from the fact, that no additional infrastructure - e.g. Bluetooth or Wifi networks - is required, which saves a lot of cost. Next show up UITP Global Public Transport Summit in Montréal/Canada 15 - 17 May 2017 AIT booth: # 2D100 https://uitpsummit.org/exhibitors/ait-austrian-institute-of-technology-gmbh/ About AIT The AIT Austrian Institute of Technology is Austria's largest non-university research institute. With its eight Centers, AIT regards itself as a highly specialised research and development partner for industry. Its researchers focus on the key infrastructure issues of the future: Energy, Health & Bioresources, Digital Safety & Security, Vision, Automation & Control, Mobility Systems, Low-Emission Transport, Technology Experience and Innovation Systems & Policy. Throughout the whole of Austria - in particular at the main locations Wien Tech Gate, Wien TECHbase, Wien Muthgasse, Seibersdorf, Wiener Neustadt, Ranshofen and Leoben - around 1,300 employees carry out research on the development of those tools, technologies and solutions that will keep Austria's economy fit for the future in line with our motto "Tomorrow Today". Contact: Juliane Thoß Marketing and Communications AIT Austrian Institute of Technology Center for Low-Emission Transport Center for Mobility Systems T +43 (0)50550-6322 juliane.thoss@ait.ac.at | www.ait.ac.at A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/f4a3b481-b86f-493d-8e86-f8ac20fa334e A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/98b44314-4bb3-490a-9f6d-60b29fcd32eb


10 patients with Mycobacterium Abscessus Complex (MABSC) are expected to enroll in the trial Data expected in the fourth quarter of 2017 REHOVOT, Israel and NEW YORK, Aug. 07, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage anti-microbial therapeutic company treating respiratory diseases with nitric oxide (NO), today announced the dosing of the first patient in its Phase 2 trial targeting NTM patients with MABSC. “We are excited to advance this potentially life changing therapy for NTM patients with the dosing of the first patient in our trial. MABSC is a difficult to treat infection with a high unmet medical need. Intensive NO treatment for just 21 days may obviate the need for long term, toxic and costly antibiotic therapy, significantly benefitting patients suffering with this disease,” said Steve Lisi, Chief Executive Officer of AIT Therapeutics. AIT has completed a Phase 1 clinical safety trial on healthy subjects, and has acquired positive human clinical data on over 50 patients with cystic fibrosis, bronchiolitis, and NTM. These data show that inhaled NO is safe with strong evidence of activity. AIT’s device is designed to safely and effectively deliver 160 ppm NO to patients for the treatment of severe lung infections. The single arm, open label Phase 2 trial is expected to enroll 10 patients. Patients will be treated with inhaled NO at a concentration of 160 ppm for 30 minutes. This treatment will be administered intermittently 3 or 5 times per day over a 21-day period. The primary endpoint is safety as measured by NO-related serious adverse events (SAEs) over the 21-day treatment period. Secondary endpoints include a 6-minute walk test and Mycobacterium abscessus load in sputum. Data are expected to be announced in the fourth quarter of 2017. NTM infection is a rare and serious condition causing debilitating pulmonary disease associated with increased morbidity and mortality. NTM is an emerging public health concern worldwide because of its multi-drug antibiotic resistance. Current treatment guidelines suggest a combination of multiple antibiotics delivered continually over one to two years. These complex, expensive and invasive regimens have a poor record for the treatment MABSC. AIT’s system is designed to effectively deliver 160 ppm NO which has been proven to eliminate bacteria, viruses, fungi and other microbes from the lungs and may work against antibiotic resistant bacteria. “MABSC comprises a group of rapidly growing, multi-drug resistant bacteria that are responsible for a wide spectrum of pulmonary diseases predominantly in vulnerable hosts with underlying structural lung disease such as cystic fibrosis, bronchiectasis, COPD and lung cancer. The conventional anti-microbial therapies are disappointing and new treatment modalities are urgently needed. At this time, Nitric Oxide shows great promise,” said Andrew Colin, M.D., Professor of Cystic Fibrosis and Pediatric Pulmonology and Director of the pediatric CF program at the Miller School of Medicine, University of Miami. Lea Bentur, M.D., a Principal Investigator of the NO-NTM study, and Professor of Cystic Fibrosis and Pediatric Pulmonology and Director of the Pediatric Pulmonary unit at the Rambam Medical Center in Israel commented, “Currently available antibiotics for NTM have a very low success rate against MABSC. Nitric Oxide has the potential to not only save lives, but also improve the quality of life for MABSC patients.” “Current treatment for NTM lung disease requires one to two years of treatment with multiple antibiotics that have very limited efficacy, especially in MABSC, and carry the risk of adverse events that can impact quality of life well beyond the end of treatment. The NO-NTM trial offers patients a 21-day treatment that may significantly shorten the duration of toxic antibiotic therapy,” added Ori Efrati, M.D., a Principal Investigator of the NO-NTM study and Professor of Cystic Fibrosis and Pediatric Pulmonology and the Head of the Pediatric Pulmonology Unit at the Safra Children’s Hospital in Tel Hashomer, Israel. In addition to the trial in NTM patients, AIT is also conducting a Phase 3 trial in infants hospitalized due to bronchiolitis. The majority of admissions with bronchiolitis are caused by respiratory syncytial virus (RSV).  RSV is a common and highly transmissible virus that infects the respiratory tract of most children before their second birthday. While in most infants RSV presents with minor respiratory symptoms, a small percentage develop serious lower airway infections, termed bronchiolitis, which can become life-threatening. The absence of treatment options for bronchiolitis limits the care of these extremely sick infants to largely supportive measures.  Data from this trial are expected in the first half of 2018. Regulatory filings for both bronchiolitis and NTM are anticipated prior to the end of 2019. About NO Nitric oxide (NO) is a powerful molecule proven to play a critical role in a broad array of biological functions. In the airways, NO is believed to play a key role in the innate immune system at concentrations of approximately 200 ppm. In vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, both gram positive and gram negative, but also against other diverse organisms including mycobacteria, fungi, yeast and parasites, and has the potential to eliminate their multi-drug resistant strains. About AIT Therapeutics Inc. AIT Therapeutics Inc. is a clinical-stage anti-microbial therapeutic company using nitric oxide (NO) to treat respiratory and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections which are not effectively addressed with current standards of care. AIT Therapeutics is advancing its revolutionary respiratory targeted system in clinical trials for the treatment of bronchiolitis (RSV) and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com. Forward-Looking Statement This press release contains “forward-looking statements.”  Forward-looking statements include statements about our expectations, beliefs, or intentions regarding our product offerings, business, financial condition, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” “likely,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to marketable products; our ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by our products; our ability to enforce our patents against infringers and to defend our patent portfolio against challenges from third parties; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of our product candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; our dependence on collaborators; and our short operating history. We undertake no obligation to update, and we do not have a policy of updating or revising, these forward-looking statements, except as required by applicable law.


News Article | June 14, 2017
Site: globenewswire.com

REHOVOT, Israel and NEW YORK, June 14, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical stage anti-microbial therapeutic company treating respiratory diseases with nitric oxide (NO), today announced the appointment of Steve Lisi as Chief Executive Officer, effective June 14, 2017.  Mr. Lisi is currently Chairman of the Board. Amir Avniel, the current CEO and a founder, will transition to become President and Chief Operating Officer of the company. “2017 will be a transformative year for AIT Therapeutics and I am thrilled to be appointed CEO at this important time,” said Mr. Lisi.  “We have already successfully completed a reverse merger, raised gross proceeds of $10.9 million in an equity offering and our stock is now trading on the Nasdaq OTC marketplace.  Our vision is to make our proprietary NO formulation and device an effective treatment for multiple lung infections and diseases. We expect to report Phase 2 data in nontuberculous mycobacteria (NTM) in the fourth quarter of 2017 and Phase 3 data in bronchiolitis (RSV) exacerbations requiring hospitalizations in the first quarter of 2018.  I believe that AIT has the potential to deliver significant value while positively impacting the lives of patients. I look forward to working with AIT's executive team and Board to advance the company further." “On behalf of the board, we are very pleased that Amir Avniel will assume an ongoing leadership role at AIT as President and COO, building on his important accomplishments to date,” continued Mr. Lisi. Mr. Lisi has extensive executive management and investment experience covering the life sciences industry. Since 1995 he has been involved with investing in private and public healthcare companies ranging from $2 million to $300 billion in market capitalization.  He has been a director of AIT Therapeutics since January 2017 and was appointed Chairman of the Board in May 2017.  He previously served as Senior Vice President of Business and Corporate Development at Flamel Technologies (renamed Avadel Pharmaceuticals – AVDL) where he restructured the company and transformed it from $100 million in enterprise value to $1 billion in three years.  Prior to his position with Flamel, Mr. Lisi held positions as an analyst at Mehta and Isaly (now OrbiMed) and a portfolio manager at SAC Capital, Millennium Partners, and Deerfield Management. Mr. Lisi is the Co-Founder and Chairman of the Board of Mico Innovations, a next-generation novel bare metal stent company and a board member of Incysus, Ltd., a leading-edge immunotherapy company targeting solid tumors.  Mr. Lisi received a Master in International Business from Pepperdine University. About AIT Therapeutics Inc. AIT Therapeutics Inc. is a clinical-stage anti-microbial therapeutic company developing novel non-antibiotic anti-microbial therapeutics for respiratory diseases based on nitric oxide (NO) as well as other indications.  The Company is applying its therapeutic expertise to prevent and treat lower respiratory tract infections, many of which cannot effectively be addressed with current standards of care.  AIT Therapeutics is advancing its revolutionary respiratory targeted system in a pipeline of clinical trials for the treatment of bronchiolitis (RSV) exacerbations, and nontuberculous mycobacteria (NTM).  For more information, visit www.AIT-Pharm.com. Forward-Looking Statements This press release contains “forward-looking statements”.  Forward-looking statements include statements about our expectations, beliefs or intentions regarding our product offerings, business, financial condition, results of operations, strategies or prospects.  You can identify such forward-looking statements by the words “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” “likely,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters.  Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.  Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements.  These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to marketable products; our ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by our products; our ability to enforce our patents against infringers and to defend our patent portfolio against challenges from third parties; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of our product candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; our dependence on collaborators; and our short operating history. We undertake no obligation to update, and we do not have a policy of updating or revising, these forward-looking statements, except as required by applicable law.


News Article | August 11, 2017
Site: globenewswire.com

REHOVOT, Israel and NEW YORK, Aug. 11, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage anti-microbial therapeutic company treating respiratory diseases with nitric oxide (NO), today announced financial results for the three- and six-months ended June 30, 2017. “I am impressed with the team at AIT as we have realized our goal of having two human clinical trials underway in 2017, just six months after our last financing. With data from both trials expected in the near term, we could see a significant shift in the prognosis for both bronchiolitis and MABSC patients,” said Steve Lisi, Chairman of the Board and Chief Executive Officer of AIT Therapeutics. “In the fourth quarter of this year, we anticipate presenting data from our NO-NTM abscessus Phase 2 clinical trial. NTM is a devastating condition and MABSC is the worst form of it. The current standard-of-care, a combination of several antibiotics administered over one to two years, has a very poor record of treating MABSC,” stated Mr. Lisi. “There are over 150,000 infant hospitalizations annually for bronchiolitis in the United States. As previously announced, data from our Phase 2 trial demonstrated a 24-hour reduction in hospital length-of-stay, and we look forward to reporting the data from our ongoing NO-BRO Phase 3 trial in the first half of 2018,” added Mr. Lisi. “We are extremely pleased to announce the addition of Erick Lucera to our Board of Directors,” remarked Mr. Lisi.  “Erick has extensive experience in the biotech industry and has a proven record of success.  We welcome his counsel and his perspective will certainly enhance AIT going forward.” The single-arm, open-label Phase 2 trial is expected to enroll 10 patients with MABSC, who are refractory to standard-of-care. Patients will be treated with inhaled NO at a concentration of 160 ppm for 30-minutes, in addition to treatment with standard-of-care. Our inhaled NO treatment will be administered intermittently 5 times per day over a 14-day period, followed by a 7-day period with 3 treatments per day. The primary endpoint is safety, as measured by NO-related serious adverse events (SAEs), over the 21-day treatment period. Secondary endpoints include a 6-minute walk test and Mycobacterium abscessus load in sputum. Data are expected to be announced in the fourth quarter of 2017. The prospective, randomized, double-blind, controlled Phase 3 trial is expected to enroll 84-120 patients, aged 0-12 months, who are hospitalized due to bronchiolitis.  Patients will receive either standard-of-care (typically oxygen and hydration) or standard-of-care plus inhaled NO at a concentration of 160 ppm for 30 minutes 5 times per day for up to 5 days.  The primary endpoint is hospital length-of-stay (LOS).  Secondary endpoints are time required to achieve a clinical score of 5 or less on the modified Tal score and time required to achieve oxygen saturation (SaO ) of 92% or greater.  Data are expected to be announced in the first half of 2018.  Please refer to our website for more information on the modified Tal score. NTM infection is a rare and serious condition causing debilitating pulmonary disease associated with increased morbidity and mortality. NTM is an emerging public health concern worldwide because of its multi-drug antibiotic resistance. Current treatment guidelines suggest a combination of multiple antibiotics delivered continually over one to two years. These complex, expensive and invasive regimens have a poor record in the treatment of MABSC. AIT’s system is designed to effectively deliver 160 ppm NO, which has been proven to eliminate bacteria, viruses, fungi and other microbes from the lungs and may work against antibiotic resistant bacteria. The majority of hospital admissions of infants with bronchiolitis are caused by respiratory syncytial virus (RSV).  RSV is a common and highly transmissible virus that infects the respiratory tract of most children before their second birthday. While most infants with RSV present with minor respiratory symptoms, a small percentage develop serious lower airway infections, termed bronchiolitis, which can become life-threatening. The absence of treatment options for bronchiolitis limits the care of these extremely sick infants to largely supportive measures.  AIT’s system is designed to effectively deliver 160 ppm NO, which has been proven to eliminate bacteria, viruses, fungi and other microbes from the lungs and may work against antibiotic resistant bacteria. The Company had cash and cash equivalents of $5.2 million on June 30, 2017.  This compares to $7.1 million on March 31, 2017. For the three months ended June 30, 2017, the Company posted a net loss of $2.9 million, or $0.46 per share, compared to a net loss of $1.0 million, or $0.44 per share, for the same period in 2016.  The weighted number of shares outstanding were 6,241,942 and 2,207,449 for the three months ended June 30, 2017 and June 30, 2016, respectively. Research and development expenses were $591 thousand for the three months ended June 30, 2017, as compared to $271 thousand for the three months ended June 30, 2016. The increase was primarily due to costs related to clinical trials. General and administrative expenses were $2.5 million for the three months ended June 30, 2017, as compared to $160 thousand for the three months ended June 30, 2016. The increase of $2.3 million was primarily due to an increase of approximately $1.8 million in stock-based compensation, mainly due to grants to Board members and employees, a non-cash expense, and an increase in legal and other costs. Net financial income for the three months ended June 30, 2017 was $187 thousand, compared to a financial expense of $332 thousand for the three months ended June 30, 2016. The net financial income in the second quarter of 2017 resulted primarily due to a revaluation of warrants granted to investors in connection with the Company’s private placements in January 2017 and March 2017. As of June 30, 2017, the Company had cash and short-term deposits of $5.2 million and working capital of $4.4 million. Throughout 2017, the Company will continue to invest primarily in research and development efforts for the Company’s clinical trials in bronchiolitis and NTM abscessus. AIT Therapeutics management will host a conference call for investors today, August 11, 2017, beginning at 10:30 a.m. Eastern time to discuss these results and answer questions.  Shareholders and other interested parties may participate in the call by dialing (877) 874-1588 (domestic) or (719) 325-2499 (international) and entering passcode 9831107. The call also will also be available via a webcast that can be accessed on the Company's website at www.ait-pharm.com or by using the following link: http://public.viavid.com/index.php?id=125702. A replay of the call will be accessible two hours after its completion through August 25, 2017 by dialing (844) 512-2921 (domestic) or (412) 317-6671 (international) and entering passcode 9831107. The call will also be archived on the Company website for 30 days at www.ait-pharm.com. Nitric oxide (NO) is a powerful molecule proven to play a critical role in a broad array of biological functions. In the airways, NO is believed to play a key role in the innate immune system at concentrations of approximately 200 ppm. In vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, both gram-positive and gram-negative, but also against other diverse organisms including mycobacteria, fungi, yeast and parasites, and has the potential to eliminate their multi-drug resistant strains. AIT Therapeutics Inc. is a clinical-stage anti-microbial therapeutic company using nitric oxide (NO) to treat respiratory and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections, which are not effectively addressed with current standards of care. AIT Therapeutics is advancing its revolutionary respiratory targeted system in clinical trials for the treatment of bronchiolitis (RSV) and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com. This press release contains “forward-looking statements.”  Forward-looking statements include statements about our expectations, beliefs, or intentions regarding our product offerings, business, financial condition, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” “likely,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to marketable products; our ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by our products; our ability to enforce our patents against infringers and to defend our patent portfolio against challenges from third parties; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of our product candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; our dependence on collaborators; and our short operating history. We undertake no obligation to update, and we do not have a policy of updating or revising, these forward-looking statements, except as required by applicable law.


News Article | June 15, 2017
Site: globenewswire.com

REHOVOT, Israel and NEW YORK, June 15, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical stage anti-microbial therapeutic company treating respiratory diseases with nitric oxide (NO), today announced that Steve Lisi, Chief Executive Officer, will conduct investor meetings at the JMP Securities Life Science Conference, taking place on June 20-21, 2017 in New York City. About AIT Therapeutics Inc. AIT Therapeutics Inc. is a clinical-stage anti-microbial therapeutic company developing novel non-antibiotic anti-microbial therapeutics for respiratory diseases based on nitric oxide (NO) as well as other indications.  The Company is applying its therapeutic expertise to prevent and treat lower respiratory tract infections, many of which cannot effectively be addressed with current standards of care.  AIT Therapeutics is advancing its revolutionary respiratory targeted system in a pipeline of clinical trials for the treatment of bronchiolitis (RSV) exacerbations, and nontuberculous mycobacteria (NTM).  For more information, visit www.AIT-Pharm.com.


Vienna, 23.02.2017 The key to a well-designed airport is to understand how passengers interact with their environment and how visual information influences their orientation and navigation behavior. Of particular importance is wayfinding information, which often competes with other visual stimuli such as advertising. Wayfinding has to be an integral part of the design process to create more intuitive architectural spaces where passengers navigate instinctively. Evaluating the design from a passenger's wayfinding perspective already in the planning phase can prevent wrong design choices which might result in higher costs at later stages. EXPERIENCE is a consulting service based on virtual reality technologies which offers a novel method for an interactive exploration and analysis of architectural models and designs before they are built. It uses a test environment allowing persons to walk through virtual 3D models of airports while measuring their movement, visual attention and relevant behavioral characteristics. For a high level of realism, EXPERIENCE combines immersive visual computing technologies, characteristic soundscapes and cutting-edge crowd simulations - based on the framework SIMULATE, which is also used for evacuation and capacity analysis of infrastructures. As a result, the passenger wayfinding experience can be evaluated by quantifying several passenger-oriented aspects (detailed passenger-route-analysis, visibility of static and dynamic signage, etc.) in customized scenarios with a representative cross-section of user groups (age, nationality, etc.). EXPERIENCE was developed by experts from the AIT Austrian Institute of Technology Center for Mobility Systems in close cooperation with Fraunhofer Austria Research GmbH. This collaboration enabled the development of an ideal solution for architects, operators of large infrastructures and public spaces, transportation planners and consultants. It effectively supports the evaluation of architecture and identifies issues ahead of time, resulting in reduced need for re-work and project cost savings. As such it revolutionizes wayfinding planning processes and enables to test the acceptance of the terminal visibility as a whole or of its subsystems and components. EXPERIENCE improves pedestrian flows - as well as the performance of designs - and increases customer satisfaction leading to greater usage and turnover. EXPERIENCE was successfully used in the planning phase of Vienna's new Central Railway Station to improve the guidance of people through the facility. How to find us at Passenger Terminal Expo 2017: AIT Austrian Institute of Technology GmbH Hall 8, Booth 5100 Contact: Silvia Bernkopf, +43 664 8251470 About AIT The AIT Austrian Institute of Technology is Austria's largest non-university research institute. With its eight Centers, AIT regards itself as a highly specialised research and development partner for industry. Its researchers focus on the key infrastructure issues of the future: Energy, Health & Bioresources, Digital Safety & Security, Vision, Automation & Control, Mobility Systems, Low-Emission Transport, Technology Experience and Innovation Systems & Policy. Throughout the whole of Austria - in particular at the main locations Wien Tech Gate, Wien TECHbase, Wien Muthgasse, Seibersdorf, Wiener Neustadt, Ranshofen and Leoben - around 1,300 employees carry out research on the development of those tools, technologies and solutions that will keep Austria's economy fit for the future in line with our motto "Tomorrow Today". Contact: Juliane Thoß Marketing and Communications AIT Austrian Institute of Technology Center for Low-Emission Transport Center for Mobility Systems T +43 (0)50550-6322 juliane.thoss@ait.ac.at | www.ait.ac.at


News Article | December 22, 2016
Site: www.businesswire.com

Based in Lynnwood, WA, Nova-Tech is a designer and integrator of critical assembly automation, materials handling and friction stir welding equipment and tooling for the aerospace and space launch industries. Nova-Tech’s talented engineering and executive team will join the AIT family while continuing to operate as a distinct business line and brand led by Nova-Tech’s CEO, William B. (“Benny”) Teal. “In our industry, Nova-Tech is synonymous with engineering excellence and dedicated customer service,” said Ed Chalupa, AIT’s Chairman and CEO. “Benny and his team have established a culture that perfectly exemplifies the entrepreneurship and innovation that has always driven the aerospace industry forward. Nova-Tech’s strong presence in international markets and adjacent sectors like space launch is particularly unique in our industry.” “The adoption of automation in aerospace is accelerating, just as the automation supply base is consolidating offshore,” said Teal. “It’s exciting to have a partner in this environment and to be a part of a platform with this scale of technology and engineering talent.” AIT’s investment in Nova-Tech represents its second transaction in the aerospace automation sector following the purchase earlier this month of KUKA Systems Aerospace North America (as recently reorganized) in a carve-out transaction from KUKA Systems North America LLC. The financial terms of the transaction were not disclosed. AIT is the world's largest provider of automation, factory integration and tooling solutions dedicated to the global aerospace and defense industries. From its headquarters in Plano, Texas, AIT designs, manufactures and installs automated tooling and equipment for the assembly of aerospace structures. AIT serves the world’s largest and most technologically advanced aerospace OEMs and Tier 1 suppliers, including Boeing, Airbus, Lockheed Martin, Northrop Grumman, Spirit AeroSystems, Triumph and Bombardier. AIT has facilities in the United States, Canada, Spain and Sweden. Nova-Tech is in its forty-eighth year and is well established as a premier supplier of manufacturing solutions to the worldwide aerospace industry. Headquartered in Lynnwood, Washington, it also has offices in South Carolina, Alabama, Germany, Brazil and the U.K. The company serves all the major commercial aircraft manufacturers, and is also engaged with defense work and space launch vehicles.


Patent
AIT Inc | Date: 2016-01-29

A method for monitoring medication intake activity comprising receiving patient data, receiving prescription data, receiving drug data, receiving risk element data and calculating, by a processor, a patients risk level for abusing controlled substances based on the drug data, the prescription data, the risk element data, and the patient data


SINGAPORE, BEIJING, and SAN DIEGO, Dec. 8, 2016 /PRNewswire/ -- Novogene, a leading commercial provider of genomic services and solutions with cutting edge next-generation sequencing and bioinformatics expertise; AITbiotech Pte Ltd, a Singapore biotechnology company; and the Genome...

Loading AIT Inc collaborators
Loading AIT Inc collaborators